{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T18:03:43Z","timestamp":1793901823425,"version":"4.8.0"},"update-to":[{"DOI":"10.1002\/14651858.cd012035","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,11,27]],"date-time":"2017-11-27T00:00:00Z","timestamp":1511740800000}}],"reference-count":92,"publisher":"Wiley","issue":"11","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012035.pub2","type":"journal-article","created":{"date-parts":[[2017,11,27]],"date-time":"2017-11-27T00:41:16Z","timestamp":1511743276000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Thrombopoietin receptor agonists for prevention and treatment of chemotherapy-induced thrombocytopenia in patients with solid tumours"],"prefix":"10.1002","volume":"2017","author":[{"given":"Xia","family":"Zhang","sequence":"first","affiliation":[{"name":"Chinese PLA General Hospital; Department of Oncology; Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunhai","family":"Chuai","sequence":"additional","affiliation":[{"name":"Navy General Hospital; Department of Obstetrics and Gynaecology; Fucheng Road Beijing China 100048"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Nie","sequence":"additional","affiliation":[{"name":"No.425 Hospital of Chinese PLA; Department of Internal Medicine; Sanya Bay Road No.86 Sanya China 572000"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiming","family":"Wang","sequence":"additional","affiliation":[{"name":"Navy General Hospital; Department of Obstetrics and Gynaecology; Fucheng Road Beijing China 100048"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanghai","family":"Dai","sequence":"additional","affiliation":[{"name":"Chinese PLA General Hospital; Department of Oncology; Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,11,27]]},"reference":[{"key":"10.1002\/14651858.CD012035.pub2-BIB0001|cit1","unstructured":"497115\/003 A double-blind, randomized, multicenter, placebo-controlled, parallel group, dose ranging study to assess the efficacy, safety, and pharmacokinetics of an oral thrombopoietin receptor agonist (SB497115-GR) administered at 50, 75, and 100 mg to cancer patients receiving multiple cycles of chemotherapy GlaxoSmithKline (GSK) Clinical Study Register"},{"key":"10.1002\/14651858.CD012035.pub2-BIB0002|cit2","doi-asserted-by":"crossref","unstructured":"Bussel JB McHutchison J Provan D Jagiello-Gruzfeld A Rafi R Goodison S Safety of eltrombopag, an oral non-peptide platelet growth factor, in the treatment of thrombocytopenia: results of four randomized, placebo-controlled studies Blood 2007 Nov 1299","DOI":"10.1182\/blood.V110.11.1299.1299"},{"issue":"6","key":"10.1002\/14651858.CD012035.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1007\/s00280-013-2150-9","article-title":"Population PK\/PD modeling of eltrombopag in subjects with advanced solid tumors with chemotherapy-induced thrombocytopenia","volume":"71","author":"Hayes","year":"2013 Jun","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"10","key":"10.1002\/14651858.CD012035.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1185\/03007995.2010.510051","article-title":"A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin\/paclitaxel for advanced solid tumors","volume":"26","author":"Kellum","year":"2010 Oct","journal-title":"Current Medical Research and Opinion"},{"key":"10.1002\/14651858.CD012035.pub2-BIB0005|cit5","doi-asserted-by":"crossref","unstructured":"Kellum A Jagiello-Gruszfeld A Bondarenko IN Rafi R Giangiulio P Messam C Hepatobiliary (HB) safety of eltrombopag administered after carboplatin+paclitaxel (Carb+Pac) in patients (pts) with solid tumors Journal of Clinical Oncology 2009 abstr e20667","DOI":"10.1200\/jco.2009.27.15_suppl.e20667"},{"key":"10.1002\/14651858.CD012035.pub2-BIB0006|cit6","unstructured":"NCT00102726 SB-497115 (oral thrombopoietin receptor agonist) versus placebo in adult cancer patients receiving chemotherapy ClinicalTrials.gov"},{"key":"10.1002\/14651858.CD012035.pub2-BIB0007|cit7","unstructured":"20050154 Dose\/schedule finding trial of AMG 531 for chemotherapy-induced thrombocytopenia (CIT) in non-small cell lung cancer (NSCLC) Amgen Clinical Trials"},{"key":"10.1002\/14651858.CD012035.pub2-BIB0008|cit8","unstructured":"NCT00413283 Dose\/schedule finding trial of romiplostim for chemotherapy-induced thrombocytopenia (CIT) in non-small cell lung cancer (NSCLC) ClinicalTrials.gov"},{"issue":"2","key":"10.1002\/14651858.CD012035.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/S1359-6349(09)71939-1","article-title":"Safety of romiplostim for treatment of chemotherapy-induced thrombocytopenia (CIT) in patients with advanced non-small cell lung cancer (NSCLC)","volume":"7","author":"Natale","year":"2009 Sep","journal-title":"European Journal of Cancer Supplements"},{"key":"10.1002\/14651858.CD012035.pub2-BIB0010|cit10","unstructured":"112765 (phase I) A randomized, blinded, placebo-controlled, two-phase, sequential cohort, dose finding study to assess the safety and efficacy of an oral thrombopoietin receptor agonist, eltrombopag (SB-497115-GR), administered to patients with solid tumors receiving gemcitabine monotherapy or the combination of gemcitabine plus carboplatin or cisplatin GlaxoSmithKline (GSK) Clinical Study Register"},{"key":"10.1002\/14651858.CD012035.pub2-BIB0011|cit11","unstructured":"NCT01147809 (phase I) Safety and efficacy study for solid tumor patients treated with eltrombopag ClinicalTrials.gov"},{"issue":"1","key":"10.1002\/14651858.CD012035.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/cam4.326","article-title":"Eltrombopag with gemcitabine-based chemotherapy in patients with advanced solid tumors: a randomized phase I study","volume":"4","author":"Winer","year":"2015 Jan","journal-title":"Cancer Medicine"},{"key":"10.1002\/14651858.CD012035.pub2-BIB0013|cit13","doi-asserted-by":"crossref","unstructured":"Winer ES Safran H Karaszewska B Richards DA Hartner L Forget F Safety and efficacy of eltrombopag (epag) versus placebo (pbo) for the treatment (tx) of chemotherapy-induced thrombocytopenia (CIT) in patients with solid tumors receiving gemcitabine (gem)-based chemotherapy (ctx): A phase I study Journal of Clinical Oncology 2012 abstr 9117","DOI":"10.1200\/jco.2012.30.15_suppl.9117"},{"issue":"22","key":"10.1002\/14651858.CD012035.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1182\/blood.V128.22.3748.3748","article-title":"Romiplostim for treatment and prevention of chemotherapy-associated thrombocytopenia","volume":"128","author":"Al-Samkari","year":"2016","journal-title":"Blood"},{"key":"10.1002\/14651858.CD012035.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/1471-2407-13-121","article-title":"Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide","volume":"13","author":"Chawla","journal-title":"BMC Cancer"},{"issue":"suppl 6","key":"10.1002\/14651858.CD012035.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/neuonc\/now212.598","article-title":"Thrombopoietin receptor agonists are effective in treating chemotherapy-induced thrombocytopenia, in patients with gliomas undergoing myelotoxic treatment","volume":"18","author":"Dardis","year":"2016","journal-title":"Neuro-Oncology"},{"issue":"22","key":"10.1002\/14651858.CD012035.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1182\/blood.V128.22.4926.4926","article-title":"Low doses of eltrombopag are safe and effective in the prophylaxis of the chemotherapy-induced thrombocytopenia (CIT)","volume":"128","author":"Iuliano","year":"2016","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1002\/14651858.CD012035.pub2-BIB0018|cit18","first-page":"593","article-title":"Eltrombopag low doses as prophylaxis of the chemotherapy-induced thrombocytopenia (CIT) in cancer patients treated with platinum based chemotherapy","volume":"101","author":"Iuliano","year":"2016","journal-title":"Haematologica"},{"issue":"22","key":"10.1002\/14651858.CD012035.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1182\/blood.V128.22.530.530","article-title":"Single-center experience with romiplostim for management of chemotherapy-induced thrombocytopenia (CIT)","volume":"128","author":"Miao","year":"2016","journal-title":"Blood"},{"key":"10.1002\/14651858.CD012035.pub2-BIB0020|cit20","unstructured":"NCT02052882 An open label phase II study of romiplostim for chemotherapy induced thrombocytopenia ClinicalTrials.gov"},{"issue":"15 suppl","key":"10.1002\/14651858.CD012035.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"10134","DOI":"10.1200\/JCO.2016.34.15_suppl.10134","article-title":"Romiplostim management of chemotherapy-induced thrombocytopenia","volume":"34","author":"Soff","year":"2016","journal-title":"Journal of Clinical Oncology"},{"issue":"suppl 1","key":"10.1002\/14651858.CD012035.pub2-BIB0022|cit22","first-page":"590","article-title":"The role of romiplostim in chemotherapy-induced thrombocytopenia treatment","volume":"101","author":"Urena","year":"2016","journal-title":"Haematologica"},{"issue":"15 suppl","key":"10.1002\/14651858.CD012035.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"e20616","DOI":"10.1200\/jco.2009.27.15_suppl.e20616","article-title":"Evaluation of AMG 531 in chemotherapy-induced thrombocytopenia (CIT): Results of a phase I\/II study","volume":"27","author":"Vadhan-Raj","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD012035.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood.V116.21.1544.1544","article-title":"Randomized, double-blind, placebo-controlled, dose and schedule-finding study of AMG 531 In Chemotherapy-Induced Thrombocytopenia (CIT): results of a phase I\/II study","volume":"116","author":"Vadhan-Raj","year":"2010","journal-title":"Blood"},{"key":"10.1002\/14651858.CD012035.pub2-BIB0025|cit25","unstructured":"112765 (phase II) A randomized, blinded, placebo-controlled, two-phase, sequential cohort, dose finding study to assess the safety and efficacy of an oral thrombopoietin receptor agonist, eltrombopag (SB-497115-GR), administered to patients with solid tumors receiving gemcitabine monotherapy or the combination of gemcitabine plus carboplatin or cisplatin GlaxoSmithKline (GSK) Clinical Study Register"},{"key":"10.1002\/14651858.CD012035.pub2-BIB0026|cit26","unstructured":"NCT01147809 (phase II) Safety and efficacy study for solid tumor patients treated with eltrombopag ClinicalTrials.gov"},{"key":"10.1002\/14651858.CD012035.pub2-BIB0027|cit27","doi-asserted-by":"crossref","unstructured":"Winer ES Safran H Forget F Karaszewska B Bauer S Khan D Safety and efficacy of eltrombopag (EPAG) vs placebo (PBO) for treatment of chemotherapy (CTx)-induced thrombocytopenia (TCP) in patients (Pts) with solid tumors receiving gemcitabine (GEM)-based CTx: A phase 2 study Journal of Clinical Oncology 2015 abstr 9602","DOI":"10.1200\/jco.2015.33.15_suppl.9602"},{"issue":"6","key":"10.1002\/14651858.CD012035.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s12185-017-2319-9","article-title":"Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: a randomized, placebo-controlled phase 2 study","volume":"106","author":"Winer","year":"2017 Dec","journal-title":"International Journal of Hematology"},{"key":"10.1002\/14651858.CD012035.pub2-BIB0029|cit29","unstructured":"EUCTR2013-002564-69-DE Double-blind, placebo-controlled multicenter phase II trial to evaluate the efficacy and safety of romiplostim for the treatment of chemotherapy-induced thrombocytopenia in subjects with relapsed ovarian cancer (2nd or further line) European Union Clinical Trials Register"},{"key":"10.1002\/14651858.CD012035.pub2-BIB0030|cit30","unstructured":"NCT02093325 A randomized, double blind, placebo-controlled study to assess the efficacy and safety of eltrombopag as a rescue of isolated chemotherapy-induced thrombocytopenia in patients with gynecologic cancer ClinicalTrials.gov"},{"key":"10.1002\/14651858.CD012035.pub2-BIB0031|cit31","unstructured":"Harper SE Important information concerning updates to the US Nplate\u00ae (romiplostim) Prescribing Information 2011 http:\/\/www.amgen.com\/pdfs\/products\/NPlate-DHCP-2011-07-27.pdf.pdf (accessed 10 April 2012)"},{"issue":"4","key":"10.1002\/14651858.CD012035.pub2-BIB0032|cit32","first-page":"437","article-title":"A multi-center clinical trial of recombinant human thrombopoietin in the treatment of chemotherapy-induced thrombocytopenia in patients with solid tumor","volume":"26","author":"Bai","year":"2004","journal-title":"Zhongguo Yi Xue Ke Xue Yuan Xue Bao"},{"issue":"7","key":"10.1002\/14651858.CD012035.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1182\/blood.V99.7.2599","article-title":"Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor","volume":"99","author":"Basser","year":"2002","journal-title":"Blood"},{"issue":"4","key":"10.1002\/14651858.CD012035.pub2-BIB0034|cit34","first-page":"477","article-title":"Association betweenindustry funding and statistically significant pro-industryfindings in medical and surgical randomized trials","volume":"170","author":"Bhandari","year":"2004 Feb","journal-title":"Canadian Medical Association Journal"},{"issue":"1","key":"10.1002\/14651858.CD012035.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/10428190600909115","article-title":"The role of interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with solid tumors, lymphoma, acute myeloid leukemia and bone marrow failure syndromes","volume":"48","author":"Bhatia","year":"2007","journal-title":"Leukemia & Lymphoma"},{"issue":"4 Pt 2","key":"10.1002\/14651858.CD012035.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1016\/j.lpm.2014.02.008","article-title":"Thrombopoietic agents: there is still much to learn","volume":"43","author":"Bussel","year":"2014 Apr","journal-title":"Presse Medicale"},{"issue":"1","key":"10.1002\/14651858.CD012035.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1365-2141.2004.05281.x","article-title":"Phase I\/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study","volume":"128","author":"Cairo","year":"2005 Jan","journal-title":"British Journal of Haematology"},{"issue":"12","key":"10.1002\/14651858.CD012035.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1002\/cncr.11447","article-title":"Pharmacoeconomic analysis of oprelvekin (recombinant human interleukin-11) for secondary prophylaxis of thrombocytopenia in solid tumour patients receiving chemotherapy","volume":"97","author":"Cantor","year":"2003 Jun","journal-title":"Cancer"},{"issue":"12","key":"10.1002\/14651858.CD012035.pub2-BIB0039|cit39","first-page":"948","article-title":"Expert consensus on rational use of recombinant human IL-11 for thrombocytopenia in solid tumor patients","volume":"32","author":"Chinese Society of Clinical Oncology","year":"2010 Dec","journal-title":"Chinese Journal of Oncology"},{"issue":"11","key":"10.1002\/14651858.CD012035.pub2-BIB0040|cit40","first-page":"876","article-title":"Expert consensus on diagnosis and treatment of chemotherapy-induced thrombocytopenia in cancer patients (2014 edition)","volume":"36","author":"Chinese Society of Clinical Oncology","year":"2014","journal-title":"Chinese Journal of Oncology"},{"key":"10.1002\/14651858.CD012035.pub2-BIB0041|cit41","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. 2009 The US National Cancer Institute (NCI)"},{"key":"10.1002\/14651858.CD012035.pub2-BIB0042|cit42","unstructured":"Deeks JJ Higgins JPT Altman DG (editors) Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration Available from www.cochrane-handbook.org 2011"},{"issue":"3","key":"10.1002\/14651858.CD012035.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"issue":"10","key":"10.1002\/14651858.CD012035.pub2-BIB0044|cit44","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012055.pub2","article-title":"Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to chronic bone marrow failure: a meta-analysis and systematic review","author":"Desborough","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD012035.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/bjh.12328","article-title":"Advances in megakaryocytopoiesis and thrombopoiesis: from bench to bedside","volume":"161","author":"Deutsch","year":"2013 Jun","journal-title":"British Journal of Haematology"},{"issue":"9","key":"10.1002\/14651858.CD012035.pub2-BIB0046|cit46","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009883.pub2","article-title":"Thrombopoietin mimetics for patients with myelodysplastic syndromes","author":"Dodillet","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD012035.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1200\/JCO.2001.19.4.1137","article-title":"Incidence, cost, and outcomes of bleeding and chemotherapy dose modification among solid tumor patients with chemotherapy-induced thrombocytopenia","volume":"19","author":"Elting","year":"2001","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1002\/14651858.CD012035.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/cncr.11195","article-title":"Cost of chemotherapy-induced thrombocytopenia among patients with lymphoma or solid tumors","volume":"97","author":"Elting","year":"2003","journal-title":"Cancer"},{"issue":"1","key":"10.1002\/14651858.CD012035.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.exphem.2004.09.006","article-title":"Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist","volume":"33","author":"Erickson-Miller","year":"2005","journal-title":"Experimental Hematology"},{"issue":"5","key":"10.1002\/14651858.CD012035.pub2-BIB0050|cit50","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004269.pub3","article-title":"Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation","author":"Estcourt","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD012035.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1177\/107327481502200107","article-title":"Platelet transfusion for patients with cancer","volume":"22","author":"Fletcher","year":"2015","journal-title":"Cancer Control"},{"issue":"2","key":"10.1002\/14651858.CD012035.pub2-BIB0052|cit52","first-page":"168","article-title":"Chemotherapy-induced thrombocytopenia and clinical bleeding in patients with gynecologic malignancy","volume":"36","author":"Hashiguchi","year":"2015","journal-title":"European Journal of Gynaecological Oncology"},{"issue":"11","key":"10.1002\/14651858.CD012035.pub2-BIB0053|cit53","first-page":"2841","article-title":"Treatment patterns and outcomes in management of solid cancer patients suffering from thrombocytopenia in Penang hospital","volume":"12","author":"Hassan","year":"2011","journal-title":"Asian Pacific Journal of Cancer Prevention"},{"key":"10.1002\/14651858.CD012035.pub2-BIB0054|cit54","unstructured":"Higgins JPT Deeks JJ (editors) Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration Available from www.cochrane-handbook.org 2011"},{"key":"10.1002\/14651858.CD012035.pub2-BIB0055|cit55","unstructured":"Higgins JPT Altman DG Sterne JAC (editors) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration Available from www.cochrane-handbook.org 2011"},{"key":"10.1002\/14651858.CD012035.pub2-BIB0056|cit56","unstructured":"Higgins JPT Deeks JJ Altman DG (editors) Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011).The Cochrane Collaboration Available from www.cochrane-handbook.org 2011"},{"issue":"2","key":"10.1002\/14651858.CD012035.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/bjh.12772","article-title":"Thrombopoietin from beginning to end","volume":"165","author":"Hitchcock","year":"2014 Apr","journal-title":"British Journal of Haematology"},{"issue":"21","key":"10.1002\/14651858.CD012035.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1093\/jnci\/83.21.1546","article-title":"Effects of recombinant human granulocyte-macrophage colony-stimulating factor on myelosuppression induced by multiple cycles of high-dose chemotherapy in patients with advanced breast cancer","volume":"83","author":"Hoekman","year":"1991","journal-title":"Journal of the National Cancer Institute"},{"issue":"3","key":"10.1002\/14651858.CD012035.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1200\/JCO.2009.24.7999","article-title":"Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia","volume":"28","author":"Kantarjian","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1002\/14651858.CD012035.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"205","DOI":"10.7326\/M14-1589","article-title":"Platelet transfusion: a clinical practice guideline from the AABB","volume":"162","author":"Kaufman","year":"2015 Feb","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD012035.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1182\/blood-2006-10-019315","article-title":"New thrombopoietic growth factors","volume":"109","author":"Kuter","year":"2007","journal-title":"Blood"},{"issue":"Suppl 69","key":"10.1002\/14651858.CD012035.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1600-0609.2007.00999.x","article-title":"New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura","volume":"80","author":"Kuter","year":"2008","journal-title":"European Journal of Haematology"},{"key":"10.1002\/14651858.CD012035.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/B978-1-4557-2296-9.00008-7","article-title":"General aspects of thrombocytopenia, platelet transfusions, and thrombopoietic growth factors","volume-title":"Consultative Hemostasis and Thrombosis","author":"Kuter","year":"2013"},{"issue":"4","key":"10.1002\/14651858.CD012035.pub2-BIB0064|cit64","first-page":"282","article-title":"Managing thrombocytopenia associated with cancer chemotherapy","volume":"29","author":"Kuter","year":"2015 Apr","journal-title":"Oncology (Williston Park)"},{"key":"10.1002\/14651858.CD012035.pub2-BIB0065|cit65","unstructured":"Lefebvre C Manheimer E Glanville J Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration Available from www.cochrane-handbook.org 2011"},{"issue":"7","key":"10.1002\/14651858.CD012035.pub2-BIB0066|cit66","first-page":"542","article-title":"Effectiveness and safety of recombinant human interleukin-11 in the treatment of chemotherapy-induced thrombocytopenia","volume":"28","author":"Lei","year":"2006 Jul","journal-title":"Chinese Journal of Oncology"},{"issue":"6","key":"10.1002\/14651858.CD012035.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/CCO.0b013e32831369b2","article-title":"The use of second-generation thrombopoietic agents for chemotherapy-induced thrombocytopenia","volume":"20","author":"Levy","year":"2008","journal-title":"Current Opinion in Oncology"},{"issue":"12","key":"10.1002\/14651858.CD012035.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/blood.V98.12.3241","article-title":"Thrombocytopenia caused by the development of antibodies to thrombopoietin","volume":"98","author":"Li","year":"2001","journal-title":"Blood"},{"issue":"7","key":"10.1002\/14651858.CD012035.pub2-BIB0069|cit69","first-page":"1064","article-title":"Prophylactic recombinant human thrombopoietin treatment alleviates chemotherapy-induced thrombocytopenia in tumor patients","volume":"32","author":"Li","year":"2012","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"issue":"2","key":"10.1002\/14651858.CD012035.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/bjh.12758","article-title":"Interpreting the developmental dance of the megakaryocyte: a review of the cellular and molecular processes mediating platelet formation","volume":"165","author":"Machlus","year":"2014 Apr","journal-title":"British Journal of Haematology"},{"issue":"5","key":"10.1002\/14651858.CD012035.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s00520-013-2074-2","article-title":"Romiplostim for management of chemotherapy-induced thrombocytopenia","volume":"22","author":"Parameswaran","year":"2014","journal-title":"Supportive Care in Cancer"},{"issue":"24","key":"10.1002\/14651858.CD012035.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analysis of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD012035.pub2-BIB0073|cit73","unstructured":"Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5) 2014"},{"issue":"2","key":"10.1002\/14651858.CD012035.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/j.1537-2995.2012.03727.x","article-title":"The influence of bleeding on trigger changes for platelet transfusion in patients with chemotherapy-induced thrombocytopenia","volume":"53","author":"Rioux-Mass\u00e9","year":"2013 Feb","journal-title":"Transfusion"},{"issue":"5","key":"10.1002\/14651858.CD012035.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1200\/JCO.2001.19.5.1519","article-title":"Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology","volume":"19","author":"Schiffer","year":"2001 Mar","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD012035.pub2-BIB0076|cit76","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JPT Vist GE Glasziou P Guyatt GH Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration Available from www.cochrane-handbook.org 2011"},{"issue":"5","key":"10.1002\/14651858.CD012035.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/cncr.25545","article-title":"Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes","volume":"117","author":"Sekeres","year":"2011","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD012035.pub2-BIB0078|cit78","unstructured":"Sterne JAC Egger M Moher D (editors) Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration Available from www.cochrane-handbook.org 2011"},{"issue":"12","key":"10.1002\/14651858.CD012035.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.2165\/11594310-000000000-00000","article-title":"Thrombocytopenia in adult cancer patients receiving cytotoxic chemotherapy: results from a retrospective hospital-based cohort study","volume":"34","author":"Berg","year":"2011 Dec","journal-title":"Drug Safety"},{"key":"10.1002\/14651858.CD012035.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"issue":"1 Suppl 2","key":"10.1002\/14651858.CD012035.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1053\/j.seminhematol.2008.12.007","article-title":"Management of chemotherapy-induced thrombocytopenia: current status of thrombopoietic agents","volume":"46","author":"Vadhan-Raj","year":"2009","journal-title":"Seminars in Hematology"},{"issue":"3","key":"10.1002\/14651858.CD012035.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1053\/j.seminhematol.2010.03.004","article-title":"Clinical findings with the first generation of thrombopoietic agents","volume":"47","author":"Vadhan-Raj","year":"2010 Jul","journal-title":"Seminars in Hematology"},{"issue":"48","key":"10.1002\/14651858.CD012035.pub2-BIB0083|cit83","first-page":"809","article-title":"Platelet transfusion in hematology, oncology and surgery","volume":"111","author":"Wandt","year":"2014","journal-title":"Deutsches Arzteblatt International"},{"issue":"6","key":"10.1002\/14651858.CD012035.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.clpt.2004.08.010","article-title":"Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand","volume":"76","author":"Wang","year":"2004","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"6","key":"10.1002\/14651858.CD012035.pub2-BIB0085|cit85","first-page":"373","article-title":"Phase II clinical trial on China manufactured recombinant human interleukin-11 derivative in the prevention and treatment of chemotherapy-induced thrombocytopenia","volume":"27","author":"Wang","year":"2005 Jun","journal-title":"Chinese Journal of Oncology"},{"issue":"11","key":"10.1002\/14651858.CD012035.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1111\/j.1537-2995.2012.03634.x","article-title":"A new tool to assess bleeding severity in patients with chemotherapy-induced thrombocytopenia (CME)","volume":"52","author":"Webert","year":"2012 Nov","journal-title":"Transfusion"},{"key":"10.1002\/14651858.CD012035.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/j.clinthera.2009.11.020","article-title":"Anemia and thrombocytopenia in patients undergoing chemotherapy for solid tumors: a descriptive study of a large outpatient oncology practice database, 2000-2007","volume":"31 Pt 2","author":"Wu","year":"2009","journal-title":"Clinical Therapeutic"},{"issue":"14","key":"10.1002\/14651858.CD012035.pub2-BIB0088|cit88","first-page":"30","article-title":"Prevention and treatment of bone marrow suppression caused by antineoplastic agents","volume":"7","author":"Wu","year":"2010","journal-title":"Drug Evaluation"},{"issue":"8","key":"10.1002\/14651858.CD012035.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1007\/s00520-011-1290-x","article-title":"Multicenter, randomized study of genetically modified recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in cancer patients receiving chemotherapy","volume":"20","author":"Wu","year":"2012 Aug","journal-title":"Supportive Care in Cancer"},{"issue":"7","key":"10.1002\/14651858.CD012035.pub2-BIB0090|cit90","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008235.pub2","article-title":"TPO receptor agonist for chronic idiopathic thrombocytopenic purpura","author":"Zeng","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"24","key":"10.1002\/14651858.CD012035.pub2-BIB0091|cit91","first-page":"1508","article-title":"Clinical tolerance test of recombinant human thrombopoietin","volume":"81","author":"Zhao","year":"2001","journal-title":"Zhong hua Yi Xue Za Zhi"},{"issue":"1","key":"10.1002\/14651858.CD012035.pub2-BIB0092|cit92","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012035","article-title":"Thrombopoietin receptor agonists for prevention and treatment of chemotherapy-induced thrombocytopenia in patients with solid tumours","author":"Zhang","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD012035.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T15:02:32Z","timestamp":1625238152000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012035.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Haematological Malignancies Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,11,27]]},"references-count":92,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2017,11]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012035.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,27]]}}}